Shionogi & Co., Ltd. announced the launch of Fetroja(cefiderocol) intravenous infusion 1g vial in Japan on December 20, 2023. Furthermore, the sale of testing reagents for measuring sensitivity to Cephiderocol will commence on December 22 of this year. Fetroja is a new siderophore cephalosporin antibiotic developed by Shionogi.

On November 30, 2023, it received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for various infections caused by strains resistant to carbapenem antibiotics among sensitive strains of Escherichia coli, Citrobacter species, Klebsiella pneumoniae, Enterobacter species, Serratia marcescens, Proteus species, Morganella morganii, Pseudomonas aeruginosa, Burkholderia species, Stenotrophomonas maltophilia, and Acinetobacter species. As part of commitment to promoting the proper use of antimicrobial agents, have been actively working on the development and provision of reagents for drug susceptibility testing to enable prompt testing of bacterial sensitivity to medication, Fetroja, since its launch. By establishing a system for drug susceptibility testing concurrently with the release of Fetroja, anticipate that this medication will become a new treatment option for appropriate patients suffering from infectious diseases caused by drug-resistant bacteria.

This initiative aligns with dedication to advancing responsible and effective antimicrobial usage.